Valacyclovir
Brand names: VALACYCLOVIR HYDROCHLORIDE, VALTREX, Valacyclovir Hydrochloride, Valacyclovir hydrochloride, valacyclovir hydrochloride, Valacyclovir
Warnings
No boxed warning. Key warnings include thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), which "has occurred in patients with advanced HIV-1 disease" and in bone marrow/renal transplant recipients given high doses; acute renal failure, particularly in elderly or dehydrated patients or those with underlying renal disease; CNS effects including "agitation, hallucinations, confusion, and encephalopathy," more common in the elderly; and postmarketing reports of severe cutaneous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contraindicated in patients with hypersensitivity to valacyclovir, acyclovir, or any formulation component.
Contraindications
4 CONTRAINDICATIONS Valacyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valacyclovir, acyclovir, or any component of the formulation [see Adverse Reactions (6.3) ]. Hypersensitivity to valacyclovir (e.g., anaphylaxis), acyclovir, or any component of the formulation. ( 4 )
Overdose
10 OVERDOSAGE Caution should be exercised to prevent inadvertent overdose [see Use in Specific Populations (8.5 , 8.6) ]. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. In the event of acute renal failure and anuria, the patient may benefit from hemodialysis until renal function is restored [see Dosage and Administration (2.4) ].
Drug interactions
7 DRUG INTERACTIONS No clinically significant drug-drug or drug-food interactions with valacyclovir tablets are known [see Clinical Pharmacology (12.3) ].
Uses
In adults: treatment of cold sores (herpes labialis), genital herpes (initial episode, recurrent episodes, and chronic suppressive therapy, including reduction of transmission), and herpes zoster (shingles). In pediatric patients: cold sores in those 12 years and older, and chickenpox (varicella) in immunocompetent children 2 to less than 18 years of age.
Dosage forms & strengths
All identified pills
1000
WHITE OVAL · Valacyclovir
2 manufacturers
500
WHITE OVAL · Valacyclovir
2 manufacturers
54356
WHITE OVAL · Valacyclovir
54518
WHITE OVAL · Valacyclovir
93 7259
BLUE OVAL · Valacyclovir
3 manufacturers
93 7258
BLUE OVAL · Valacyclovir
3 manufacturers
C324500
BLUE CAPSULE · Valacyclovir
5 manufacturers
C3251000
BLUE CAPSULE · Valacyclovir
9 manufacturers
CIPLA153
BLUE CAPSULE · Valacyclovir
13 manufacturers
CIPLA154
BLUE CAPSULE · Valacyclovir
13 manufacturers
F 8
BLUE CAPSULE · Valacyclovir
26 manufacturers
F 82
BLUE CAPSULE · Valacyclovir
28 manufacturers
I 87
WHITE CAPSULE · Valacyclovir
14 manufacturers
I 86
BLUE CAPSULE · Valacyclovir
4 manufacturers
I 87
WHITE OVAL · Valacyclovir
M122
WHITE OVAL · Valacyclovir
4 manufacturers
M123
WHITE OVAL · Valacyclovir
4 manufacturers
RDY 553
BLUE CAPSULE · Valacyclovir
RDY 552
BLUE CAPSULE · Valacyclovir
RX904
BLUE CAPSULE · Valacyclovir
4 manufacturers
RX905
BLUE CAPSULE · Valacyclovir
7 manufacturers
SZ 394
BLUE CAPSULE · Valacyclovir
3 manufacturers
SZ 393
BLUE CAPSULE · Valacyclovir
4 manufacturers
V 1
BLUE OVAL · Valacyclovir
6 manufacturers
V 5
BLUE OVAL · Valacyclovir
6 manufacturers
VALTREX 1
BLUE CAPSULE · Valacyclovir
2 manufacturers
VALTREX 500
BLUE CAPSULE · Valacyclovir
4 manufacturers
VALTREX 1
BLUE OVAL · Valacyclovir
5 manufacturers
VALTREX 500
BLUE OVAL · Valacyclovir
4 manufacturers
W152
BLUE CAPSULE · Valacyclovir
5 manufacturers
W153
BLUE CAPSULE · Valacyclovir
4 manufacturers
WPI 3249
BLUE CAPSULE · Valacyclovir
5 manufacturers
WPI 3248
BLUE CAPSULE · Valacyclovir
4 manufacturers
Y131
BLUE CAPSULE · Valacyclovir
Y132
BLUE CAPSULE · Valacyclovir
Side effects
In adults, the most common adverse reactions (reported by more than 10% of patients in at least one indication) were headache, nausea, and abdominal pain. In pediatric patients under 18, headache was the only reaction reported in more than 10% of subjects.